MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial

被引:7
|
作者
Gormly, Kirsten L. [1 ]
Coscia, Claudio [1 ]
Wells, Tim [1 ]
Tebbutt, Niall [2 ]
Harvey, Jennifer A. [3 ]
Wilson, Kate [4 ]
Schmoll, Hans-Joachim [5 ]
Price, Timothy [6 ,7 ]
机构
[1] Dr Jones & Partners Med Imaging, Adelaide, SA, Australia
[2] Austin Hlth, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic, Australia
[3] Princess Alexandra Hosp, Brisbane, Qld, Australia
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] Martin Luther Univ Halle Wittenberg, Halle, Germany
[6] Univ Adelaide, Queen Elizabeth Hosp, Adelaide, SA, Australia
[7] AGITG, Adelaide, SA, Australia
关键词
audit; MRI; rectal cancer; RESECTION MARGIN; ACCURACY; MANAGEMENT;
D O I
10.1111/1754-9485.12493
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: An MRI audit substudy was conducted in patients who underwent an MRI prior to treatment in Australia and New Zealand as part of the PETACC-6 trial in locally advanced rectal cancer. Methods: A total of 82 patients from 15 centres had rectal MRI scans reviewed for technique, data included in reports and comparison of reports with blinded central reporting by two experienced radiologists. Results: In total, 82% performed minimum T2 sagittal and T2 axial oblique sequences. The high-resolution T2 sequence parameters varied significantly with only 33% obtaining a voxel size of <1.3 mm(3). The rate of inclusion of relevant findings in the reports was T3 distance in mm 21%, N stage 84%, circumferential resection margin ( CRM) status 72%, extramural venous invasion ( EMVI) status 29% and distance from the puborectalis sling 17%. In total, 31% reports included all of T stage with T3 substage, N stage and CRM involvement. In total, 17% reports included these 3 findings and EMVI. Eleven reports used a template with 82% of these including the first 3 findings. The agreement with central reporters was T stage 76%, N stage 70%, CRM status 57% and EMVI 16%. Conclusion: There is significant variation in scan quality and low rates of including all relevant findings in rectal MRI reports in the audit. The authors recommend adoption of routine sequences and template reports in both trial settings and routine practice to improve scan technique and adequacy of reports in rectal cancer MRI staging scans across Australia and New Zealand.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 50 条
  • [1] MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial
    KLM Gormly
    C Coscia
    T Wells
    N Tebbutt
    JA Harvey
    K Wilson
    H-J Schmoll
    T Price
    Cancer Imaging, 15 (Suppl 1)
  • [2] First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer
    Haustermans, K.
    Schmoll, H. J.
    Price, T.
    Nordlinger, B.
    Hofheinz, R. D.
    Daisne, J. F.
    Janssens, J.
    Schmidt, P.
    Reinel, H.
    Van Cutsem, E.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S96 - S96
  • [3] Final results of PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine plus /- oxaliplatin in locally advanced rectal cancer
    Hofheinz, R-D
    Schmoll, H-J
    Haustermans, K.
    Price, T.
    Nordlinger, B.
    Daisne, J-F
    Janssens, J.
    Brenner, B.
    Schmidt, P.
    Reinel, H.
    Hollerbach, S.
    Caca, K.
    Fauth, F.
    Hannig, C., V
    Zalcberg, J.
    Tebbutt, N.
    Mauer, M.
    Marreaud, S.
    Lutz, M.
    Van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 123 - 123
  • [4] Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.
    Schmoll, Hans-Joachim
    Haustermans, Karin
    Price, Timothy Jay
    Nordlinger, Bernard
    Hofheinz, Ralf
    Daisne, Jean-Francois
    Janssens, Jozef
    Brenner, Baruch
    Schmidt, Peter
    Reinel, Hans
    Hollerbach, Stephan
    Caca, Karel
    Fauth, Florian W. B.
    Hannig, Carla
    Zalcberg, John Raymond
    Tebbutt, Niall C.
    Mauer, Murielle E.
    Messina, Carlo G. M.
    Lutz, Manfred P.
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit
    Whitfield, Robert
    Kollias, James
    De Silva, Primali
    Zorbas, Helen
    Maddern, Guy
    ANZ JOURNAL OF SURGERY, 2012, 82 (04) : 234 - 239
  • [6] Current practice in Australia and New Zealand for defunctioning ileostomy after rectal cancer surgery with anastomosis: Analysis of the Binational Colorectal Cancer Audit
    Grupa, Vera E. M.
    Kroon, Hidde M.
    Ozmen, Izel
    Bedrikovetski, Sergei
    Dudi-Venkata, Nagendra N.
    Hunter, Ronald A.
    Sammour, Tarik
    COLORECTAL DISEASE, 2021, 23 (06) : 1421 - 1433
  • [7] The use of neoadjuvant systemic therapies in breast cancer in Australia and New Zealand: breast surgeons of Australia and New Zealand quality audit
    Duffield, Jaime A.
    Blanch, Adam J.
    Esterman, Adrian
    Bochner, Melissa A.
    ANZ JOURNAL OF SURGERY, 2023, 93 (04) : 889 - 895
  • [8] PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine plus /- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up
    Schmoll, H.
    Haustermans, K.
    Price, T.
    Nordlinger, B.
    Hofheinz, R.
    Daisne, J.
    Janssens, J.
    Brenner, B.
    Schmidt, P.
    Reinel, H.
    Hollerbach, S.
    Caca, K.
    Fauth, F.
    Hannig, C.
    Zalcberg, J.
    Tebbutt, N.
    Mauer, M.
    Marreaud, S.
    Lutz, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 107 - 107
  • [9] Guidelines for surgical audit in Australia and New Zealand
    Watters, DAK
    Green, AJ
    Van Rij, A
    ANZ JOURNAL OF SURGERY, 2006, 76 (1-2) : 78 - 83
  • [10] Impact of obesity on patients undergoing surgery for rectal cancer in Australia and New Zealand
    Yang, Phillip F.
    Ang, Zhen Hao
    Badiani, Sarit
    Berney, Christophe R.
    Morgan, Matthew J.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38 (01)